We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.23%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$402M
Cap. Flow
+$256M
Cap. Flow %
30.02%
Top 10 Hldgs %
54.49%
Holding
73
New
24
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.3M
2
AZN icon
AstraZeneca
AZN
+$41.9M
3
GSK icon
GSK
GSK
+$32.4M
4
UTHR icon
United Therapeutics
UTHR
+$28.6M
5
AMRN
Amarin Corp
AMRN
+$25.5M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.5M
2
OSUR icon
OraSure Technologies
OSUR
+$11.4M
3
HSKA
Heska Corp
HSKA
+$10.3M
4
LAB icon
Standard BioTools
LAB
+$9.68M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.33%
3 Financials 0.05%
4 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.89M 1.04%
103,764
-217,817
-68% -$18.5M
MGLN
27
DELISTED
Magellan Health Services, Inc.
MGLN
$8.67M 1.02%
+104,700
New +$8.28M
RAD
28
DELISTED
Rite Aid Corporation
RAD
$8.42M 0.99%
+532,004
New +$6.84M
AUPH icon
29
Aurinia Pharmaceuticals
AUPH
$2.17B
$8.36M 0.98%
604,368
+168,373
+39% +$2.45M
MCRB icon
30
Seres Therapeutics
MCRB
$51.3M
$8.18M 0.96%
+16,702
New +$9.78M
QDEL icon
31
QuidelOrtho
QDEL
$1.01B
$7.29M 0.86%
40,583
+31,240
+334% +$6.94M
AMRN
32
CALL
Amarin Corp
AMRN
$295M
$6.29M 0.74%
64,270
+1,065
+2% +$103K
AFMD
33
DELISTED
Affimed
AFMD
$5.61M 0.66%
96,471
-28,075
-23% -$1.32M
AMRX icon
34
Amneal Pharmaceuticals
AMRX
$6.11B
$5.38M 0.63%
1,178,153
-1,478,055
-56% -$6.55M
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.37M 0.63%
307,742
+14,465
+5% +$203K
ALT icon
36
Altimmune
ALT
$605M
$4.29M 0.5%
+380,000
New +$4.48M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.66M 0.43%
491,852
-651,359
-57% -$3.36M
FPRX
38
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.56M 0.42%
+209,155
New +$2.62M
SNY icon
39
Sanofi
SNY
$107B
$3.31M 0.39%
68,138
+18,360
+37% +$906K
HCA icon
40
HCA Healthcare
HCA
$90.5B
$2.76M 0.32%
16,754
-35,646
-68% -$5.21M
PRTA icon
41
Prothena Corp
PRTA
$479M
$2.44M 0.29%
203,328
+6,300
+3% +$74.5K
CARM
42
DELISTED
Carisma Therapeutics
CARM
$2.11M 0.25%
77,991
– –
ANAB icon
43
AnaptysBio
ANAB
$1.67B
$1.9M 0.22%
+88,334
New +$2.15M
SRDX
44
DELISTED
Surmodics
SRDX
$1.8M 0.21%
+41,299
New +$1.63M
ONCT
45
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.69M 0.2%
+17,205
New +$1.09M
OTIC
46
DELISTED
Otonomy, Inc.
OTIC
$1.64M 0.19%
253,283
-159,217
-39% -$723K
AUTL
47
Autolus Therapeutics
AUTL
$623M
$1.39M 0.16%
+154,981
New +$1.65M
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.31M 0.15%
103,829
– –
ATXS
49
DELISTED
Astria Therapeutics
ATXS
$1.12M 0.13%
+87,007
New +$1.55M
XGN icon
50
Exagen
XGN
$179M
$1.08M 0.13%
+81,603
New +$1.15M
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Eversept Partners held 73 positions worth $852M, up 89% from $450M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Eversept Partners deployed $256M of net new capital in Q4 2020, opening 24 new positions and adding to 20 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $18.5M trimmed.

  • Eversept Partners's largest Q4 2020 buy was Alexion Pharmaceuticals: 376,200 shares worth $58.8M.
  • Eversept Partners added most to AstraZeneca in Q4 2020, an estimated $41.9M increase.
  • Eversept Partners's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $18.5M.
  • Eversept Partners fully exited OraSure Technologies in Q4 2020, selling an estimated $11.4M.
  • Eversept Partners's ten largest holdings make up 54% of its $852M portfolio in Q4 2020.
  • Eversept Partners opened 24 new positions and closed 11 in Q4 2020.
  • Eversept Partners's portfolio value rose 89% quarter-over-quarter to $852M.

Based on Eversept Partners's 13F filing for Q4 2020, filed 16 Feb 2021.